Logo image
Back
Intraperitoneal catheter leads to prolongation of the time to normalization of serum CA125 levels
Journal article   Open access   Peer reviewed

Intraperitoneal catheter leads to prolongation of the time to normalization of serum CA125 levels

Scott D Richard, Paniti Sukumvanich, Jamie L Lesnock, William C McBee, Sushil Beriwal, Robert P Edwards, Kristin K Zorn and Thomas C Krivak
International journal of gynecological cancer, v 20(6), pp 932-935
Aug 2010
DOI: https://doi.org/10.1111/IGC.0b013e3181e37a54
PMID: 20683398
Featured in Collection :   UN Sustainable Development Goals @ Drexel
url
https://doi.org/10.1111/igc.0b013e3181e37a54View
Published, Version of Record (VoR)CC BY-NC-ND V4.0,  Open

Abstract

Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Biomarkers, Tumor - analysis Biomarkers, Tumor - blood CA-125 Antigen - analysis CA-125 Antigen - blood Carboplatin - administration & dosage Carboplatin - adverse effects Catheterization - adverse effects Cohort Studies Device Removal Disease-Free Survival Female Follow-Up Studies Humans Infusions, Intravenous Injections, Intraperitoneal Middle Aged Neoplasm Staging Ovarian Neoplasms - blood Ovarian Neoplasms - drug therapy Ovarian Neoplasms - mortality Paclitaxel - administration & dosage Paclitaxel - adverse effects Retrospective Studies Risk Assessment Survival Analysis Time Factors Treatment Outcome Young Adult
The intraperitoneal (IP) catheter has the potential to cause peritoneal irritation, which may contribute to an elevated CA125 level. We hypothesize that patients undergoing IP chemotherapy may have elevated CA125 values when compared with patients receiving intravenous (IV) chemotherapy. From February 2006 to July 2007, optimally debulked patients with stage III and stage IV ovarian carcinoma from a single institution were offered an outpatient IV/IP chemotherapy regimen modified from Gynecologic Oncology Group 172. They were matched to a cohort of similar patients who received IV paclitaxel and carboplatin. Demographic data and CA125 levels were collected before each cycle of chemotherapy and after the removal of the IP catheter. Statistical analysis was completed using a chi2 test with a significance level of P < 0.05. Fifty patients received the standard IV regimen, and 38 patients completed the modified IV/IP regimen. There was no statistical difference in the median CA125 values between the 2 groups during the treatment. After 6 cycles of therapy, 68.4% (26/38) of the IP cohort had a normal CA125 level before IP catheter removal compared with 78% (39/50) in the IV chemotherapy cohort (P = 0.44). After removal of the IP catheter, 86.8% (33/38) of the patients had a normal CA125 value (68.4% vs 86.8%, P = 0.049). After removal of the IP catheter, an additional 18.2% (7/38) of patients in the IP group had normalized their CA125 level. Because CA125 levels at the end of the treatment have prognostic significance, the role of the IP catheter in an elevated CA125 level must be considered.

Metrics

6 Record Views
3 citations in Web of Science
3 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being
#5 Gender Equality

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Web of Science research areas
Obstetrics & Gynecology
Oncology
Logo image